Amgen Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 251 trades in Amgen Inc (NASDAQ: AMGN) since 2013, across 58 members, worth an estimated $4.1M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 140 buys against 111 sells, a modestly buy-led skew, with Democratic members responsible for 55% of the trades and Republican members 45%. The most recent disclosure shown was filed September 2026, and Rohit Khanna has filed the most AMGN transactions among those shown, with 14. Other recent filers include David J. Taylor, Sheldon Whitehouse, and Maria Elvira Salazar. One notable disclosed move was a purchase by Marjorie Taylor Greene on September 11, 2025, up 41.4% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Amgen Inc (AMGN) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Amgen congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 David J. Taylor House | Sep 5, 2026 | Aug 26, 2026 | 10 days | Sell |  $1,001 - $15,000 | -11.14% | Self | |
David J. Taylor House | Sep 5, 2026 | Aug 26, 2026 | 10 days | Sell | $1,001 - $15,000 | -11.14% | Self | |
 Sheldon Whitehouse Senate | Sep 2, 2026 | Aug 12, 2026 | 21 days | Sell | $1,001 - $15,000 | -5.99% | Spouse | |
 Rohit Khanna House | Aug 7, 2026 | Jul 20, 2026 | 18 days | Sell | $1,001 - $15,000 | +7.44% | Spouse | |
Rohit Khanna House | Aug 7, 2026 | Jul 8, 2026 | 30 days | Buy | $1,001 - $15,000 | +6.33% | Spouse | |
Rohit Khanna House | Jul 6, 2026 | Jun 30, 2026 | 6 days | Buy | $1,001 - $15,000 | +8.05% | Spouse | |
Rohit Khanna House | Jul 6, 2026 | Jun 16, 2026 | 20 days | Buy | $1,001 - $15,000 | +12.49% | Spouse | |
David J. Taylor House | Jun 12, 2026 | Jun 5, 2026 | 7 days | Buy | $1,001 - $15,000 | +11.93% | Self | |
Rohit Khanna House | Jul 6, 2026 | Jun 2, 2026 | 34 days | Buy | $1,001 - $15,000 | +19.20% | Child | |
Rohit Khanna House | Jun 9, 2026 | May 27, 2026 | 13 days | Buy | $15,001 - $50,000 | +16.43% | Spouse |
Amgen (AMGN) congressional trading FAQ
Can members of Congress legally trade Amgen (AMGN) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Amgen (AMGN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Amgen (AMGN) trades public?
Yes. Every congressional trade in Amgen (AMGN) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Amgen (AMGN)?
Members of Congress have disclosed 251 trades in Amgen (AMGN) worth $4.1M across 58 members, according to public STOCK Act filings.
Which members of Congress have traded Amgen (AMGN)?
Recent and active filers of Amgen (AMGN) disclosures include Rohit Khanna, David J. Taylor, Maria Elvira Salazar. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Amgen (AMGN) more?
Across disclosed Amgen (AMGN) trades, 55% were by Democrats and 45% by Republicans, led by Democrats (55%).
What is the most recent congressional Amgen (AMGN) trade?
The most recent disclosed Amgen (AMGN) filing reported a sell by David J. Taylor, filed Sep 4, 2026.
Browse all stocks Congress tradesCongressional trading overviewAmgen (AMGN) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.